Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D97BHT
|
|||
| Drug Name |
Ponsegromab
|
|||
| Synonyms |
PF-06946860
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Cancer cachexia [ICD-11: MG20.0] | Phase 2 | [1] | |
| Heart failure [ICD-11: BD10-BD13] | Phase 2 | [2] | ||
| Company |
Pfzer
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Growth/differentiation factor 15 (GDF15) | Target Info | Inhibitor | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05546476) A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PONSEGROMAB IN PATIENTS WITH CANCER, CACHEXIA, AND ELEVATED CONCENTRATIONS OF GDF-15, FOLLOWED BY AN OPTIONAL OPEN-LABEL TREATMENT PERIOD (PROACC -1). U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT05492500) A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, 4-ARM STUDY TO INVESTIGATE SYMPTOMS, FUNCTION, HEALTH-RELATED QUALITY OF LIFE AND SAFETY WITH REPEATED SUBCUTANEOUS ADMINISTRATION OF PONSEGROMAB VERSUS PLACEBO IN ADULT PARTICIPANTS WITH HEART FAILURE. U.S.National Institutes of Health. | |||
| REF 3 | Current advancements in pharmacotherapy for cancer cachexia. Expert Opin Pharmacother. 2023 Apr;24(5):629-639. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.